244 related articles for article (PubMed ID: 9435795)
1. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
2. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
3. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
4. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
Dereuddre S; Delaporte C; Jacquemin-Sablon A
Cancer Res; 1997 Oct; 57(19):4301-8. PubMed ID: 9331091
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
6. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II.
Figgitt DP; Denny WA; Gamage SA; Ralph RK
Anticancer Drug Des; 1994 Jun; 9(3):199-208. PubMed ID: 8031452
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
11. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
12. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
13. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
15. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum.
Auparakkitanon S; Wilairat P
Biochem Biophys Res Commun; 2000 Mar; 269(2):406-9. PubMed ID: 10708566
[TBL] [Abstract][Full Text] [Related]
16. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
17. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
18. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
Capranico G; Supino R; Binaschi M; Capolongo L; Grandi M; Suarato A; Zunino F
Mol Pharmacol; 1994 May; 45(5):908-15. PubMed ID: 8190107
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y
Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
